The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse ...
Investigators employed the Accelerating Medicines Partnership to identify noninvasive biomarkers of lupus nephritis pathology and treatment response.
Pharmaceutical Technology on MSN

FDA approves Roche’s Gazyva for lupus nephritis

The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult ...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...
With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...
Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease ...
Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro ...
The drug is the only medicine of its kind proven to help patients with lupus nephritis regain full kidney response, the ...
Lupus continues to carry a heavy burden despite advances in immunosuppressive therapy warranting complementary care ...
The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research ...